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Abstract: Recent human studies support historical animal studies
that suggested an association between peripheral blood monocyte:
lymphocyte (ML) ratio and tuberculosis (TB) disease. To evaluate
generalizability of this finding, we modeled the association between
peripartum ML ratio and incident TB disease within 18 months
postpartum among 1202 HIV-infected women in South Africa,
Tanzania, Uganda, and Zimbabwe. The ML ratio was associated
with increased risk of TB disease independently to combination
antiretroviral therapy, World Health Organization stage, or CD4
count (adjusted hazard ratio = 1.22, 95% confidence interval: 1.07 to
1.4, P = 0.003 per 0.1 unit increase in ML ratio).
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Current methods to predict the development of tuberculosis(TB) are poor. Neither tuberculin skin tests nor interferon
gamma release assays are good predictors of risk of TB in high-
risk populations.1 Pregnant women with HIV are at particularly
high risk of TB disease because of suppression of Th1 re-
sponses during pregnancy and HIV-induced immunosuppres-
sion.2 New methods to predict TB may allow targeting of
preventive interventions. Moreover, predictive correlates of
TB disease may help to reveal pathophysiology. Although
gratifying advances in prevention of mother-to-child transmis-
sion of HIV have been achieved in sub-Saharan Africa,3 TB in
mothers has a profoundly negative direct effect on infants’ risk
of TB and indirect effect through maternal illness.4
Fletcher5 observed that infants in the Western Cape,
South Africa, who developed TB disease before 2 years of
age could be differentiated from those who did not by the
ratio of lymphoid and myeloid transcripts in blood collected
at 10 weeks of age. Because these transcripts largely originate
from monocytes and lymphocytes, respectively, we hypothe-
sized that the ratio of these cells may be similarly predictive.
We recently confirmed this hypothesis in infants born to
mothers with HIV6 and separately found that among combi-
nation antiretroviral therapy (cART)–naive adults with AIDS,
the ratio of monocytes:lymphocytes (ML) was predictive of
incident TB disease during the subsequent 5 years on cART.
These findings are consistent with animal studies from 80
years ago8–10 and historical human studies11 in which the
ML ratio was reported to be a marker of TB disease course
and prognosis. If these findings could be extended to pregnant
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women, they would add to the generalizability of the associ-
ation and be of potential use in stratifying risk of TB in this
high-risk group.
We hypothesized that increased ML ratio of peripheral
blood may be associated with incident TB disease in pregnant
women. To test this, we performed a secondary analysis of
a large multinational clinical trial. The HIV Prevention
Trials Network (HPTN) 046 study (clinicaltrials.gov:
NCT00074412) was a phase 3 randomized controlled trial
conducted in South Africa, Uganda, Zimbabwe, and Tanzania
to determine the efficacy and safety of an extended regimen of
nevirapine (NVP) to prevent breast-feeding transmission of
HIV in infants born to HIV-infected women.12,13 HIV-
infected pregnant women (.18 years) who provided
informed consent and were free of serious medical conditions
that could interfere with study compliance were screened and
enrolled in the third trimester of their pregnancy or before 7
days postpartum. The local ethics committee at each site
approved the study. At screening, women provided a medical
and obstetric history and underwent a physical examination.
Contemporary HIV treatment guidelines informed maternal
HIV treatment, and women who were receiving cART or
had previous NVP exposure were not excluded. At the time
this study was conducted, routine isoniazid preventive ther-
apy was not implemented at the study sites but TB symptom
screening was done. At a minimum, to prevent mother-to-
child transmission, participants received the HIV Network
for Prevention Trials 012 2-dose intrapartum/neonatal regi-
men of NVP.14 A physical examination was performed, and
CD4+ T-cell enumeration and complete blood count, includ-
ing white blood cell differential, were conducted in accredited
laboratories using standardized automated counters. These
clinical procedures were repeated in the women and their
infants within 7 days of delivery, at 2 and 6 weeks, and at
3, 6, 12, and 18 months postpartum. For this analysis, partic-
ipants with active TB or TB diagnosed in the puerperium
were excluded to avoid reverse causality. A priori, we spec-
ified that a fractional polynomial model would be used to
model maternal ML ratios against TB outcomes, adjusting
for baseline CD4+ T-cell count, World Health Organization
stage, and cART receipt. Analyses were conducted in R using
themfp, epiR, and rms packages. Because of insufficient power,
we elected not to evaluate infant ML ratio and TB disease.
Between June 2008 and March 2010, 1678 pregnant
women were screened in HPTN 046. For this analysis, 476
women were excluded because of loss to follow-up (n = 146),
withdrawal as the infant was not randomized or died (n = 114
and n = 64, respectively), no blood result at baseline
(n = 123), or active TB disease during pregnancy or puerpe-
rium (n = 29). Therefore, 1202 women were included in this
analysis: the baseline blood specimen was obtained at
a median of 40 interquartile range (IQR): 20–59] days before
delivery. Their median age was 27 (IQR: 23–31) years, and
their median CD4+ T-cell count was 435 cells per cubic mil-
limeter (IQR: 299–595). Clinical staging of women per-
formed at the end of the puerperium was as follows: 1006
(83.7%) stage 1, 172 (14.3%) stage 2, 16 (1.3%) stage 3, and
3 (0.3%) stage 4 (4 were missing staging information). Three
hundred twenty-eight (27.3%) participants were receiving
cART at enrollment and through the course of follow-up.
Further clinical characteristics have been reported.15
The median ML ratio at enrollment was 0.253 (IQR:
0.192–0.326), and the distribution was similar to that previ-
ously reported7 among nonpregnant HIV-infected women in
South Africa of a similar age (P = 0.76).
During 1788 years of follow-up, 12 women were
diagnosed with TB (11 pulmonary TB and 1 TB adenitis):
4 developed TB by 6 months postpartum, 7 between 6 and 12
months postpartum, and 1 between 12 and 18 months
postpartum. In fractional polynomial proportional hazards
models, the untransformed ML ratio (ie, exponent = 1) was
significantly associated with TB disease (Table 1). After
adjusting for cART receipt, CD4+ T-cell count, and World
Health Organization stage, the association remained signifi-
cant (adjusted hazard ratio = 1.22, 95% confidence interval:
1.07 to 1.4, P = 0.003). The association between increasing
ML ratio and TB disease remained significant when absolute
monocyte and absolute lymphocyte counts were included as
covariates and when the model was stratified for study site.
We performed a secondary analysis of women who
were enrolled in HPTN 046, a large multinational study in
postpartum women. The ML ratio in peripheral blood during
the last trimester was positively associated with incident TB
disease between 6 weeks and 18 months postpartum. A
limitation of this study is the relatively low incidence rate
suggesting that lack of active case finding may have led to
TABLE 1. Cox Proportional Hazards Models of TB Disease Between 6 Weeks and 18 Months Postpartum in HPTN 046 (n = 1202)*
Variable
Univariate Model Multivariate Model
HR (95% CI) P HR (95% CI) P
CD4+ T-cell count
(per 100 cell increase)
0.7 (0.5 to 0.98) 0.04 0.61 (0.37 to 1.0) 0.05
World Health Organization clinical stage
(per stage increase)
0.94 (0.24 to 3.63) 0.93 0.73 (0.17 to 3.18) 0.68
cART receipt 1.44 (0.41 to 5.1) 0.57 0.75 (0.16 to 3.41) 0.71
ML ratio (per 0.1 unit increase) 1.26 (1.12 to 1.41) ,0.0001 1.22 (1.07 to 1.4) 0.003
*A multivariable fractional polynomial model, stratified by site, was used to model the ML ratio as a fractional polynomial so as to allow for nonlinear fits. A linear fit, however,
was the most parsimonious, and the variables are therefore presented untransformed.
Bold denotes statistically significant observations.
CI, confidence interval; HR, hazard ratio.
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outcome misclassification. The resultant bias toward the null
is consistent with the small magnitude of effect. Nevertheless,
the result is robust to adjustment for confounding, and the
finding is consistent with previous studies in animals8–10 and
humans7 adding to its generalizability. The ML ratio may be
of modest use in stratifying risk of postpartum TB in
pregnant women.
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